Development of a novel c-MET-Based CTC detection platform

Tian Zhang, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, Michael R. Harrison, David S. Hsu, Patrick Healy, Jing Li, Cinthia Pi, Katherine M. Prendergast, Carey Hobbs, Sarah Gemberling, Daniel J. George, Herbert I. Hurwitz, Mark Connelly, Mariano Garcia-Blanco, Andrew J. Armstrong

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for MET-amplified cells, sensitive (40%-80%) for c-MET-overexpressed cells, and specific (100%) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6% prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.

Original languageEnglish (US)
Pages (from-to)539-547
Number of pages9
JournalMolecular Cancer Research
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Kidney Neoplasms
Renal Cell Carcinoma
Stomach Neoplasms
Colorectal Neoplasms
Stomach
Trisomy
Oncogenes
Drug Resistance
Urinary Bladder Neoplasms
Fluorescent Antibody Technique
Neoplasms
Prostatic Neoplasms
Healthy Volunteers
Leukocytes
Carcinoma
Cell Line
Antibodies
DNA

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Zhang, T., Boominathan, R., Foulk, B., Rao, C., Kemeny, G., Strickler, J. H., ... Armstrong, A. J. (2016). Development of a novel c-MET-Based CTC detection platform. Molecular Cancer Research, 14(6), 539-547. https://doi.org/10.1158/1541-7786.MCR-16-0011

Development of a novel c-MET-Based CTC detection platform. / Zhang, Tian; Boominathan, Rengasamy; Foulk, Brad; Rao, Chandra; Kemeny, Gabor; Strickler, John H.; Abbruzzese, James L.; Harrison, Michael R.; Hsu, David S.; Healy, Patrick; Li, Jing; Pi, Cinthia; Prendergast, Katherine M.; Hobbs, Carey; Gemberling, Sarah; George, Daniel J.; Hurwitz, Herbert I.; Connelly, Mark; Garcia-Blanco, Mariano; Armstrong, Andrew J.

In: Molecular Cancer Research, Vol. 14, No. 6, 01.06.2016, p. 539-547.

Research output: Contribution to journalArticle

Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, M & Armstrong, AJ 2016, 'Development of a novel c-MET-Based CTC detection platform', Molecular Cancer Research, vol. 14, no. 6, pp. 539-547. https://doi.org/10.1158/1541-7786.MCR-16-0011
Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH et al. Development of a novel c-MET-Based CTC detection platform. Molecular Cancer Research. 2016 Jun 1;14(6):539-547. https://doi.org/10.1158/1541-7786.MCR-16-0011
Zhang, Tian ; Boominathan, Rengasamy ; Foulk, Brad ; Rao, Chandra ; Kemeny, Gabor ; Strickler, John H. ; Abbruzzese, James L. ; Harrison, Michael R. ; Hsu, David S. ; Healy, Patrick ; Li, Jing ; Pi, Cinthia ; Prendergast, Katherine M. ; Hobbs, Carey ; Gemberling, Sarah ; George, Daniel J. ; Hurwitz, Herbert I. ; Connelly, Mark ; Garcia-Blanco, Mariano ; Armstrong, Andrew J. / Development of a novel c-MET-Based CTC detection platform. In: Molecular Cancer Research. 2016 ; Vol. 14, No. 6. pp. 539-547.
@article{1dd40199a0be48bbb67874f57d8705dd,
title = "Development of a novel c-MET-Based CTC detection platform",
abstract = "Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80{\%}) for MET-amplified cells, sensitive (40{\%}-80{\%}) for c-MET-overexpressed cells, and specific (100{\%}) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6{\%} prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.",
author = "Tian Zhang and Rengasamy Boominathan and Brad Foulk and Chandra Rao and Gabor Kemeny and Strickler, {John H.} and Abbruzzese, {James L.} and Harrison, {Michael R.} and Hsu, {David S.} and Patrick Healy and Jing Li and Cinthia Pi and Prendergast, {Katherine M.} and Carey Hobbs and Sarah Gemberling and George, {Daniel J.} and Hurwitz, {Herbert I.} and Mark Connelly and Mariano Garcia-Blanco and Armstrong, {Andrew J.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/1541-7786.MCR-16-0011",
language = "English (US)",
volume = "14",
pages = "539--547",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Development of a novel c-MET-Based CTC detection platform

AU - Zhang, Tian

AU - Boominathan, Rengasamy

AU - Foulk, Brad

AU - Rao, Chandra

AU - Kemeny, Gabor

AU - Strickler, John H.

AU - Abbruzzese, James L.

AU - Harrison, Michael R.

AU - Hsu, David S.

AU - Healy, Patrick

AU - Li, Jing

AU - Pi, Cinthia

AU - Prendergast, Katherine M.

AU - Hobbs, Carey

AU - Gemberling, Sarah

AU - George, Daniel J.

AU - Hurwitz, Herbert I.

AU - Connelly, Mark

AU - Garcia-Blanco, Mariano

AU - Armstrong, Andrew J.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for MET-amplified cells, sensitive (40%-80%) for c-MET-overexpressed cells, and specific (100%) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6% prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.

AB - Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for MET-amplified cells, sensitive (40%-80%) for c-MET-overexpressed cells, and specific (100%) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6% prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.

UR - http://www.scopus.com/inward/record.url?scp=84975086229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975086229&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-16-0011

DO - 10.1158/1541-7786.MCR-16-0011

M3 - Article

VL - 14

SP - 539

EP - 547

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 6

ER -